http://orcid.org/0000-0002-9702-2999
Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jeffrey Frankel, David Staskin, Susann Varano, Michael J Kennelly, Rachael A Jankowich & Cornelia Haag-Molkenteller. (2022) An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder. Therapeutics and Clinical Risk Management 18, pages 171-182.
Read now
Read now
Adrian Wagg. (2018) Choosing oral drug therapy for overactive bladder in older people. Expert Opinion on Pharmacotherapy 19:12, pages 1375-1380.
Read now
Read now
Articles from other publishers (29)
Kevin D. Li, Nikit Venishetty, Adrian M. Fernandez, Nizar Hakam, Umar Ghaffar, Shiv Gupta, Hiren V. Patel & Benjamin N. Breyer. (2024) Fragility of overactive bladder medication clinical trials: A systematic review. Neurourology and Urodynamics.
Crossref
Crossref
Saima Rajabali, Prosper Asaana, Sahar Nazari & Adrian Wagg. (2024) A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder–wet Patients over the Age of 75 Years with Mild Cognitive Impairment. European Urology Focus.
Crossref
Crossref
Roger R. Dmochowski, Diane K. Newman, Eric S. Rovner, Jacqueline Zillioux, Rena D. Malik & A. Lenore Ackerman. (2023) Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review. Advances in Therapy 40:11, pages 4741-4757.
Crossref
Crossref
R Rizvi Syeda, S Nazari, S Rajabali, W Gibson & A Wagg. (2023) ARE FRAILTY, COMORBIDITY AND AGE RELATED TO OVERACTIVE BLADDER? A COHORT STUDY. Continence 7, pages 100989.
Crossref
Crossref
Jingjun Wang, Mary E. Ritchey, Kamika Reynolds, Madeleine Carbonneau, Adam Carrera, Noelia Goti, John R. Horn & Cynthia J. Girman. (2023) Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder. Drugs - Real World Outcomes 10:3, pages 439-446.
Crossref
Crossref
Mary E. Ritchey, Jingjun Wang, Jessica C. Young, Rajat Chandra, Adam Carrera, Noelia Goti, John R. Horn & Cynthia J. Girman. (2022) CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis. Drugs - Real World Outcomes 10:1, pages 119-129.
Crossref
Crossref
Matthew R. Cooperberg, Rachel Mbassa, David Walker, William Meeks, Amy Lockefeer, Baoguo Jiang, Tina Li, Karissa Johnston & Raymond Fang. (2023) Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States. Therapeutic Advances in Urology 15, pages 175628722211505.
Crossref
Crossref
Tatiana V.D. Sanses, Jacqueline Zillioux, Rachel A. High, Katherine L. Dengler, Mary F. Ackenbom, Catherine E. DuBeau, Marianna Alperin, Adrian Wagg, Lori A. Birder, Chantale Dumoulin & Tamara Bavendam. (2023) Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment. Urogynecology 29:1S, pages S20-S39.
Crossref
Crossref
Katherine L. Dengler, Rachel A. High, Daniela C. Moga, Jacqueline Zillioux, Adrian Wagg, Catherine E. DuBeau, Mary F. Ackenbom, Marianna Alperin, Chantale Dumoulin, Lori A. Birder, Donna Mazloomdoost, H. Henry Lai, Vivian W. Sung, Shelly L. Gray & Tatiana V.D. Sanses. (2023) Overactive Bladder and Cognitive Impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report. Urogynecology 29:1S, pages S1-S19.
Crossref
Crossref
Hiroshi Nakagomi, Takahiko Mitsui, Hiroshi Shimura, Tatsuya Ihara, Satoru Kira, Norifumi Sawada & Masayuki Takeda. (2022) Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urology 22:1.
Crossref
Crossref
Jing Voon Chen, James C. Gahn, Jeffrey Nesheim & Paul N. Mudd,Jr.Jr.. (2022) Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA. PharmacoEconomics 40:10, pages 979-988.
Crossref
Crossref
Richard G. Stefanacci, Jason Yeaw, Drishti Shah, Diane K. Newman, Amy Kincaid & Paul N. MuddJr.Jr.. (2022) Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities: A Perspective From Directors of Nursing. Journal of Gerontological Nursing 48:7, pages 38-46.
Crossref
Crossref
Michael A. Weber, Cornelia Haag-Molkenteller, Jennifer King, Ann Walker, Paul N. Mudd & William B. White. (2021) Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial. Blood Pressure Monitoring 27:2, pages 128-134.
Crossref
Crossref
Noll L. Campbell, Lisa Hines, Andrew J. Epstein, David Walker, Amy Lockefeer & Aki Shiozawa. (2021) A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA. Drugs & Aging 38:12, pages 1075-1085.
Crossref
Crossref
Matthew P. Rutman, John R. Horn, Diane K. Newman & Richard G. Stefanacci. (2021) Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions. Clinical Drug Investigation 41:4, pages 293-302.
Crossref
Crossref
Susann Varano, David Staskin, Jeffrey Frankel, Denise Shortino, Rachael Jankowich & Paul N. MuddJrJr. (2021) Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study. Drugs & Aging 38:2, pages 137-146.
Crossref
Crossref
Tomas L. Griebling, Noll L. Campbell, Jeffrey Mangel, David Staskin, Sender Herschorn, Dina Elsouda & Carol R. Schermer. (2020) Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatrics 20:1.
Crossref
Crossref
Benjamin M. Brucker, Richard K. Lee & Diane K. Newman. (2020) Optimizing Nonsurgical Treatments of Overactive Bladder in the United States. Urology 145, pages 52-59.
Crossref
Crossref
Sender Herschorn, David Staskin, Carol R. Schermer, Rita M. Kristy & Adrian Wagg. (2020) Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet. Drugs & Aging 37:9, pages 665-676.
Crossref
Crossref
Arthur L. Burnett, David R. Walker, Qi Feng, Karissa M. Johnston, Greta Lozano‐Ortega, David Nimke & John C. Hairston. (2020) Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study. Neurourology and Urodynamics 39:5, pages 1378-1386.
Crossref
Crossref
Adrian Wagg, David Staskin, Eli Engel, Sender Herschorn, Rita M. Kristy & Carol R. Schermer. (2020) Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). European Urology 77:2, pages 211-220.
Crossref
Crossref
Lindsay Shirreff, Michelle AndersonColleen McDermott. (2020) Comparing written and verbal delivery of a treatment regimen to women with overactive bladder: a randomized controlled trial. Menopause 27:1, pages 76-81.
Crossref
Crossref
Gary Puckrein, David Walker, Liou Xu, Peter Congdon & Katherine Gooch. (2019) The Prevalence and Forecast Prevalence of Overactive Bladder in the Medicare Population. Clinical Medicine Insights: Urology 12, pages 117956111984746.
Crossref
Crossref
Adrian Wagg. 2019. Contemporary Pharmacotherapy of Overactive Bladder. Contemporary Pharmacotherapy of Overactive Bladder
267
290
.
Ravishankar Jayadevappa, Sumedha Chhatre, Diane K. Newman, Jerome Sanford Schwartz & Alan J. Wein. (2018) Association between overactive bladder treatment and falls among older adults. Neurourology and Urodynamics 37:8, pages 2688-2694.
Crossref
Crossref
Adrian Wagg. (2018) Anticholinergics for Overactive Bladder in Frail and Medically Complex Older People: The Case For. Drugs & Aging 35:9, pages 777-780.
Crossref
Crossref
Osamu Yokoyama, Hidetomi Yamagami, Shintaro Hiro, Shinichi Hotta & Masaki Yoshida. (2017) Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension. International Journal of Urology 25:3, pages 251-257.
Crossref
Crossref
Eleanor O. Caplan, Ibrahim M. Abbass, Brandon T. Suehs, Daniel B. Ng, Katherine Gooch, Cindy Kirby & Paul Abbott. (2018) Impact of coexisting overactive bladder in Medicare patients with osteoporosis. Archives of Gerontology and Geriatrics 75, pages 44-50.
Crossref
Crossref
William Gibson, Scott MacDiarmid, Moses Huang, Emad Siddiqui, Matthias Stölzel, Nurul Choudhury & Marcus J. Drake. (2017) Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. European Urology Focus 3:6, pages 629-638.
Crossref
Crossref